» Articles » PMID: 33251572

Health State Utilities of Patients with Heart Failure: A Systematic Literature Review

Overview
Specialty Pharmacology
Date 2020 Nov 30
PMID 33251572
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: New treatments and interventions are in development to address clinical needs in heart failure. To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic literature review was conducted to identify and summarize heart failure utility values for use in economic evaluations.

Methods: Databases were searched for articles published until June 2019 that reported health utility values for patients with heart failure. Publications were reviewed with specific attention to study design; reported values were categorized according to the health states, 'chronic heart failure', 'hospitalized', and 'other acute heart failure'. Interquartile limits (25th percentile 'Q1', 75th percentile 'Q3') were calculated for health states and heart failure subgroups where there were sufficient data.

Results: The systematic literature review identified 161 publications based on data from 142 studies. Utility values for chronic heart failure were reported by 128 publications; 39 publications published values for hospitalized and three for other acute heart failure. There was substantial heterogeneity in the specifics of the study populations, methods of elicitation, and summary statistics, which is reflected in the wide range of utility values reported. EQ-5D was the most used instrument; the interquartile limit for mean EQ-5D values for chronic heart failure was 0.64-0.72.

Conclusions: There is a wealth of published utility values for heart failure to support economic evaluations. Data are heterogenous owing to specificities of the study population and methodology of utility value elicitation and analysis. Choice of value(s) to support economic models must be carefully justified to ensure a robust economic analysis.

Citing Articles

Cost-Effectiveness of the Self-Care Management System for Heart Failure.

Nakane E, Kato T, Tanaka N, Idouji M, Yamamoto Y, Saitou W Circ Rep. 2025; 7(1):31-36.

PMID: 39802132 PMC: 11711784. DOI: 10.1253/circrep.CR-24-0088.


A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model.

Westwood M, Armstrong N, Krijkamp E, Perry M, Noake C, Tsiachristas A Health Technol Assess. 2024; 28(31):1-105.

PMID: 39023142 PMC: 11299050. DOI: 10.3310/WYGC4096.


Canadian Cost-Effectiveness of Coronary Artery Calcium Screening Based on the Multi-Ethnic Study of Atherosclerosis.

Qureshi H, Kaul P, Dover D, Blaha M, Bellows B, Mancini G JACC Adv. 2024; 3(4):100886.

PMID: 38939688 PMC: 11198549. DOI: 10.1016/j.jacadv.2024.100886.


Examining health-related quality of life in ambulatory adult patients with chronic heart failure: insights from Malaysia using EQ-5D-5L.

Tan Y, Ong S, Yong V, Khor W, Pang L, Choong Y Qual Life Res. 2024; 33(8):2181-2195.

PMID: 38839679 DOI: 10.1007/s11136-024-03674-4.


Health state utility values in patients with Ankylosing Spondylitis: a systematic review and meta-analysis.

Feng J, Zhang K, Dou L, Shi Z, Chen G, Li S Qual Life Res. 2024; 33(9):2321-2334.

PMID: 38824212 DOI: 10.1007/s11136-024-03670-8.


References
1.
McMurray J, DeMets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A . A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019; 21(5):665-675. PMC: 6607736. DOI: 10.1002/ejhf.1432. View

2.
Kansal A, Cowie M, Kielhorn A, Krotneva S, Tafazzoli A, Zheng Y . Cost-Effectiveness of Ivabradine for Heart Failure in the United States. J Am Heart Assoc. 2016; 5(5). PMC: 4889192. DOI: 10.1161/JAHA.116.003221. View

3.
Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R . Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2006; 93(4):476-82. PMC: 1861501. DOI: 10.1136/hrt.2006.089656. View

4.
de Rivas B, Permanyer-Miralda G, Brotons C, Aznar J, Sobreviela E . Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: the INCA study. Qual Life Res. 2008; 17(10):1229-38. DOI: 10.1007/s11136-008-9397-3. View

5.
Anker S, Schroeder S, Atar D, Bax J, Ceconi C, Cowie M . Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Eur J Heart Fail. 2016; 18(5):482-9. DOI: 10.1002/ejhf.516. View